Journal article
Identification of strains of rotateq rotavirus vaccine in infants with gastroenteritis following routine vaccination
CM Donato, LS Ch'Ng, KF Boniface, NW Crawford, JP Buttery, M Lyon, RF Bishop, CD Kirkwood
Journal of Infectious Diseases | OXFORD UNIV PRESS INC | Published : 2012
Abstract
Background. RotaTeq vaccine was introduced into the Australian National Immunisation Program in 2007. This study identified and characterised rotavirus strains excreted by infants who presented with symptoms of gastroenteritis following recent RotaTeq vaccination. Methods. Fecal samples (N = 61) from children who developed gastroenteritis following recent RotaTeq vaccination were forwarded to the Australian Rotavirus Surveillance Program (ARSP). RotaTeq-positive samples were genotyped and regions of the VP3, VP4, VP6, and VP7 genes were sequenced. Also, 460 rotavirus-positive ARSP routine surveillance samples were analyzed by dot-blot Northern hybridization to detect RotaTeq vaccine-derived ..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
[ "C. D. K. is supported by a National Health and Medical Research Council Career Development Award fellowship (609347). The Australian Rotavirus Surveillance Program was supported by grants from the Department of Health and Aging, Canberra, Australia; GlaxoSmithKline; and CSL. This research was also supported by the Victorian Government's Operational Infrastructure Support Program.", "N. W. C. and J. P. B. have acted as chief investigators for epidemiological studies sponsored by vaccine manufacturers (CSL) and have had trial serological testing performed by vaccine manufacturers (Merck). Industry-sourced honoraria for sitting on advisory boards, lecturing, travel expenses, and grants for attendance at scientific meetings are paid directly to an educational administrative fund held by Murdoch Childrens Research Institute. C. D. K., J. P. B., and R. F. B. are the codevelopers of an investigational rotavirus vaccine. C. D. K. is director of the Australian Rotavirus Surveillance Program, which is supported by research grants from vaccine manufacturers. All other authors report no potential conflicts." ]